EN
EN
总部位于神户的Carna Biosciences宣布与烨辉医药达成AS-1763在大中华区开发和商业化的使用授权协议
March 16, 2020

KOBE March 16, 2020 - Carna Biosciences Inc. (JASDAQ: 4572) today announced that it has entered into a license agreement with BioNova Pharmaceuticals Limited (BioNova) to develop and commercialize AS-1763, a novel next-generation non-covalent Bruton's tyrosine kinase (BTK) inhibitor for the Greater China territory.